市場調査レポート

商品コード

1447734

性器ヘルペス市場の評価：タイプ (診断・治療)・投与経路 (経口・注射・局所)・エンドユーザー (病院薬局・小売薬局・オンライン薬局・その他)・地域別の機会および予測 (2017～2031年)

Genital Herpes Market Assessment, By Type [Diagnosis, Treatment], Route of Administration [Oral, Injectable, Topical], End-user [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others], Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年03月11日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 225 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 705,420円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 893,532円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,285,432円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の性器ヘルペスの市場規模は、2023年の22億5,000万米ドルから、2024年から2031年の予測期間中は5.24%のCAGRで推移し、2031年には33億9,000万米ドルの規模に成長すると予測されています。

世界の性器ヘルペス市場はさまざまな要因によって形成されています。これらには、性器ヘルペスの有病率の上昇、認知度の向上、外用薬の需要の増加、HSV診断の革新、アシクロビル耐性HSV感染症の開発、研究への注力強化などが含まれます。

性器ヘルペスの有病率の上昇はもっとも重要な要因の一つです。世界で数百万人が性病に罹患しており、その数は増加の一途をたどっています。その結果、兆候を制御し、蔓延を阻止するための効率的な治療法や薬剤の必要性が高まっています。性器ヘルペスに対する意識の高まりは市場に影響を与えるもう一つの側面です。より多くの人々が性器ヘルペスの危険性と影響について認識するようになっているため、教育と予防措置の必要性が高まっています。新しい治療法や診断機器のR&Dへの資金援助も増加しています。

性器ヘルペスの有病率の増加

世界の性器ヘルペス市場は、性器ヘルペスの有病率の増加により、かなりの速度で拡大しています。患者数の増加が治療需要を牽引し、医薬品、診断薬、関連サービスの新たな市場が開発されています。現在の基本推定によれば、全世界で5億人以上が性器ヘルペスに苦しんでいます。ヘルペスの推定有病率は、生涯感染であるため年齢とともに上昇し、WHO African Region (AFRO) や女性ではHSV-2の有病率が高いです。

認知度の向上

啓発キャンペーンの拡大も市場を牽引する主な要因の1つです。性器ヘルペス市場は、予防、早期診断、効率的な管理技術に重点が置かれる中で、認知度が高まるにつれて着実に拡大すると予想されています。性病、特に性器ヘルペスに関する一般的な知識が高まるにつれて、教育、予防技術、治療の選択肢に対するニーズが高まる見通しです。政府機関や医療機関のイニシアチブも人々を教育し、感染についての知識を深め、できるだけ早く医療機関を受診するよう動機付けるのに役立っています。

当レポートでは、世界の性器ヘルペスの市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1.Global Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 2.Global Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 3.Global Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 4.Global Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 5.Global Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 6.Global Genital Herpes Market Share (%), By Region, 2017-2031F
Figure 7.North America Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 8.North America Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 9.North America Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 10.North America Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 11.North America Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 12.North America Genital Herpes Market Share (%), By Country, 2017-2031F
Figure 13.United States Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 14.United States Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 15.United States Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 16.United States Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 17.United States Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 18.Canada Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 19.Canada Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 20.Canada Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 21.Canada Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 22.Canada Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 23.Mexico Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 24.Mexico Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 25.Mexico Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 26.Mexico Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 27.Mexico Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 28.Europe Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 29.Europe Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 30.Europe Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 31.Europe Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 32.Europe Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 33.Europe Genital Herpes Market Share (%), By Country, 2017-2031F
Figure 34.Germany Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 35.Germany Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 36.Germany Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 37.Germany Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 38.Germany Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 39.France Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 40.France Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 41.France Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 42.France Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 43.France Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 44.Italy Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 45.Italy Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 46.Italy Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 47.Italy Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 48.Italy Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 49.United Kingdom Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 50.United Kingdom Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 51.United Kingdom Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 52.United Kingdom Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 53.United Kingdom Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 54.Russia Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 55.Russia Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 56.Russia Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 57.Russia Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 58.Russia Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 59.Netherlands Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 60.Netherlands Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 61.Netherlands Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 62.Netherlands Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 63.Netherlands Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 64.Spain Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 65.Spain Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 66.Spain Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 67.Spain Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 68.Spain Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 69.Turkey Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 70.Turkey Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 71.Turkey Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 72.Turkey Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 73.Turkey Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 74.Poland Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 75.Poland Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 76.Poland Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 77.Poland Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 78.Poland Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 79.South America Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 80.South America Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 81.South America Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 82.South America Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 83.South America Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 84.South America Genital Herpes Market Share (%), By Country, 2017-2031F
Figure 85.Brazil Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 86.Brazil Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 87.Brazil Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 88.Brazil Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 89.Brazil Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 90.Argentina Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 91.Argentina Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 92.Argentina Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 93.Argentina Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 94.Argentina Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 95.Asia-Pacific Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 96.Asia-Pacific Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 97.Asia-Pacific Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 98.Asia-Pacific Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 99.Asia-Pacific Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 100.Asia-Pacific Genital Herpes Market Share (%), By Country, 2017-2031F
Figure 101.India Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 102.India Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 103.India Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 104.India Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 105.India Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 106.China Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 107.China Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 108.China Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 109.China Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 110.China Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 111.Japan Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 112.Japan Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 113.Japan Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 114.Japan Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 115.Japan Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 116.Australia Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 117.Australia Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 118.Australia Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 119.Australia Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 120.Australia Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 121.Vietnam Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 122.Vietnam Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 123.Vietnam Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 124.Vietnam Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 125.Vietnam Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 126.South Korea Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 127.South Korea Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 128.South Korea Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 129.South Korea Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 130.South Korea Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 131.Indonesia Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 132.Indonesia Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 133.Indonesia Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 134.Indonesia Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 135.Indonesia Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 136.Philippines Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 137.Philippines Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 138.Philippines Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 139.Philippines Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 140.Philippines Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 141.Middle East & Africa Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 142.Middle East & Africa Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 143.Middle East & Africa Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 144.Middle East & Africa Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 145.Middle East & Africa Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 146.Middle East & Africa Genital Herpes Market Share (%), By Country, 2017-2031F
Figure 147.Saudi Arabia Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 148.Saudi Arabia Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 149.Saudi Arabia Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 150.Saudi Arabia Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 151.Saudi Arabia Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 152.UAE Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 153.UAE Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 154.UAE Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 155.UAE Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 156.UAE Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 157.South Africa Genital Herpes Market, By Value, in USD Billion, 2017-2031F
Figure 158.South Africa Genital Herpes Market, By Volume, in Million Units, 2017-2031F
Figure 159.South Africa Genital Herpes Market Share (%), By Type, 2017-2031F
Figure 160.South Africa Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
Figure 161.South Africa Genital Herpes Market Share (%), By End-user, 2017-2031F
Figure 162.By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 163.By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 164.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 165.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11141

Global genital herpes market is projected to witness a CAGR of 5.24% during the forecast period, 2024-2031, growing from USD 2.25 billion in 2023 to USD 3.39 billion in 2031. The global genital herpes market is shaped by various factors. These include an increase in the prevalence of genital herpes, a rise in awareness, increasing demand for topical medications, innovations in HSV diagnosis, development of acyclovir-resistant HSV infections, and increased focus on research.

The rise in the prevalence of genital herpes is one of the most important factors. Millions of people are afflicted with STDs globally, and the number of cases is rising. Consequently, there is an increasing need for efficient therapies and drugs to control the signs and stop the spread. Growing awareness of genital herpes is another aspect influencing the global genital herpes market. The need for education and preventative measures is growing as more people are becoming aware of the dangers and repercussions of genital herpes. Funding for research and development of novel therapies and diagnostic instruments has increased.

The market for topical treatments for genital herpes is expanding due to the rising consumer demand propelling the growth of the global genital herpes market. Many patients choose topical therapies as they are simple to use and may be administered directly to the area that is affected. As a result, new topical drugs with reduced side effects and increased effectiveness have been developed. The global genital herpes market is being shaped by developments in HSV diagnosis. More rapid and accurate viral detection is possible with the development of new diagnostic techniques, which will enable early diagnosis and treatment.

The emergence of HSV infections resistant to acyclovir is another reason propelling the expansion of global genital herpes market. Novel and creative treatments are required to control the infection as the virus gets more resistant to conventional ones. Lastly, the market for genital herpes is expanding due to the greater emphasis on research. The likelihood of discovering novel treatments and cures increases with increased funds and resources allocated to research and development. These variables are influencing the global genital herpes market and propelling business expansion.

For instance, in September 2023, the U.S. National Institutes of Health laid out a strategic plan for Herpes Vaccine Research. The plan outlines a framework for HSV research with four strategic priorities, from expanding the understanding of the biology, pathophysiology, and epidemiology of HSV, quickening the pace of research to enhance HSV diagnosis, refining treatment approaches while pursuing a cure, and promoting research to prevent HSV infection.

Increase in the Prevalence of Genital Herpes

The global genital herpes market is expanding at a significant rate due to the increasing prevalence of genital herpes. The growing number of cases drives the treatment demand, which opens new markets for pharmaceuticals, diagnostics, and related services. Based on current estimates, over 500 million individuals globally suffer from genital herpes. The estimated prevalence of herpes rose with age as it is a lifetime infection and WHO African Region (AFRO) and women had a higher prevalence of HSV-2. Biologic vulnerability to HIV and HSV-2 is higher in women. Women in the WHO Africa Region are most likely to be exposed to HIV and have high HSV-2 prevalence, which increases their chance of contracting HIV and has detrimental effects on their health and well-being. Herpes symptoms can be more severe and frequent among those who have both HSV-2 and HIV, or who are coping with other illnesses that affect their immune systems.

Rise in Awareness

The expansion of awareness campaigns is one of the major factors driving the global genital herpes market. The market for genital herpes is anticipated to expand steadily as awareness grows and with a focus on prevention, early diagnosis, and efficient management techniques. The need for education, prevention techniques, and treatment choices increases as public knowledge of STDs, particularly genital herpes, rises. Due to increased awareness, appropriate behavior and a proactive attitude towards sexual health are encouraged, which propels the expansion of global genital herpes market. Governmental and healthcare organizations' initiatives help educate people and become more informed about infection and motivated them to seek medical attention as soon as possible.

The United Nations Fund for Population Activities (UNFPA) introduced "Just Ask!" in July 2023 as a chatbot to raise awareness of sexual and reproductive health and rights in India. It is a digital engagement platform powered by artificial intelligence (AI) designed to educate teenagers and young adults about their rights and sexual and reproductive health. Experts from UNFPA on sexual and reproductive health created the chatbot, which was released in close cooperation with the Madhya Pradesh government's Department of Public Health and Family Welfare and the National Health Mission (NHM).

Increasing Demand for Topical Medications

The growing demand for topical medications is increasing the market size of genital herpes globally. Herpes simplex virus infections of the skin, mucous membranes, and genitals are treated with topical medicine. Due to their advantages over oral treatments, topical therapies are becoming more and more popular in the global genital herpes market. Topical drugs are easier to apply than tablets or capsules since they are typically available in cream, gel, or ointment forms. Topical formulations are appealing to patients and healthcare professionals due to benefits such as convenience and ease of administration. Topical treatments can be applied directly to the lesion or affected area, offering faster relief and possibly fewer side effects than oral medications, which must first travel through the digestive system before reaching the infection site.

For instance, Zydus Lifesciences declared in March 2023 that has received the US Food and Drug Administration's (USFDA) final approval for Acyclovir Cream. Acyclovir is a member of the antiviral drug class. Acyclovir lotion is used to treat genital herpes.

Innovations in HSV Diagnosis

The global genital herpes market is undergoing a revolution due to the advancements in diagnosis techniques that are greatly improving patient results. The developments improve the effectiveness of diagnosis and the management and control of diseases, which in turn improves patient care and quality of life. Early diagnosis of HSV infections is now possible due to the development of faster and more reliable testing techniques, which lower the risk of transmission and enable timely treatment commencement. Innovative diagnostic technologies are boosting demand for genital herpes testing and treatment options, influencing the future landscape of the market by helping healthcare providers diagnose HSV infections more accurately.

The Truenat HSV 1/2 herpes test was introduced in January 2023 by Molbio Diagnostics. Approved by the Central Drug Standard Control Organisation (CDSCO), it is an RT-PCR test for herpes diagnosis that uses chips. There is no need for additional setup or equipment because the test is compatible with the current Truelab infrastructure.

Growing European Market

The global genital herpes market is growing significantly in Europe for several reasons. Large healthcare budgets are allotted in nations like Germany and the United Kingdom, allowing for investments in R&D and access to cutting-edge genital herpes therapies. Increased knowledge and understanding of genital herpes in these nations motivate people to seek prompt medical care, which fuels demand for genital herpes treatments and aids in the growth of the global genital herpes market. Furthermore, Europe's strict regulatory environment encourages market expansion. It is anticipated that the region will continue to grow steadily due to its favorable high level of awareness of cutting-edge STD treatment alternatives and patient demographics.

AiCuris, a German clinical-stage biopharmaceutical company, announced in July 2023 that it was concentrating on producing Pritelivir, a treatment for acyclovir-resistant herpes simplex virus infections, in phase 3 of development, to further strengthen its pipeline for infectious diseases.

Future Market Scenario (2024 - 2031F)

Social media and digital health platforms that educate young people about sexual and reproductive health are becoming more and more popular, which is contributing to the growth of the worldwide genital herpes market.

Robotic process automation is increasingly being used in the manufacturing of drugs used for treatment of genital herpes which will drive the global genital herpes market in the future.

AI-based digital diagnostic tools are increasingly being used for screening and diagnosing STIs driving the global genital herpes market.

The rise in the global genital herpes market will be fueled by changing lifestyles, as higher infection rates will lead to increased need for treatment.

Key Players Landscape and Outlook

Cooperation among academic institutions, healthcare providers, and other industry players is common in global genital herpes market. Small and medium-sized businesses are working together to make use of each other's experience, gain access to more resources, and broaden their reach in the market. These businesses have a competitive edge due to their capacity to introduce novel, efficient treatments to the market. Collaborations aid in the creation of novel antiviral medications, therapeutic vaccinations, and creative delivery methods, among other forms of new medical treatments. Patents and intellectual property rights give businesses protection and exclusivity for their creative treatment ideas, which makes them competitive.

A collaborative agreement to develop, produce, and market live vaccines against herpes simplex viruses (HSV-1 and HSV-2) in China was announced in October 2023 by Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (MH) and Rational Vaccines (RVx).

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Genital Herpes Market Outlook, 2017-2031F

4.1.Market Size & Forecast
- 4.1.1.By Value
- 4.1.2.By Volume
4.2.By Type
- 4.2.1.Diagnosis
- 4.2.2.Treatment
  - 4.2.2.1.Acyclovir
  - 4.2.2.2.Famciclovir
  - 4.2.2.3.Valacyclovir
  - 4.2.2.4.Others
4.3.By Route of Administration
- 4.3.1.Oral
- 4.3.2.Injectable
- 4.3.3.Topical
4.4.By End-user
- 4.4.1.Hospital Pharmacies
- 4.4.2.Retail Pharmacies
- 4.4.3.Online Pharmacies
- 4.4.4.Others
4.5.By Region
- 4.5.1.North America
- 4.5.2.Europe
- 4.5.3.Asia-Pacific
- 4.5.4.South America
- 4.5.5.Middle East and Africa
4.6.By Company Market Share (%), 2023

5.Global Genital Herpes Market Outlook, By Region, 2017-2031F

5.1.North America*
- 5.1.1.Market Size & Forecast
  - 5.1.1.1.By Value
  - 5.1.1.2.By Volume
- 5.1.2.By Type
  - 5.1.2.1.Diagnosis
  - 5.1.2.2.Treatment
  - 5.1.2.2.1.Acyclovir
  - 5.1.2.2.2.Famciclovir
  - 5.1.2.2.3.Valacyclovir
  - 5.1.2.2.4.Others
- 5.1.3.By Route of Administration
  - 5.1.3.1.Oral
  - 5.1.3.2.Injectable
  - 5.1.3.3.Topical
- 5.1.4.By End-user
  - 5.1.4.1.Hospital Pharmacies
  - 5.1.4.2.Retail Pharmacies
  - 5.1.4.3.Online Pharmacies
  - 5.1.4.4.Others
- 5.1.5.United States*
  - 5.1.5.1.Market Size & Forecast
  - 5.1.5.1.1.By Value
  - 5.1.5.1.2.By Volume
  - 5.1.5.2.By Type
  - 5.1.5.2.1.Diagnosis
  - 5.1.5.2.2.Treatment
  - 5.1.5.2.2.1.Acyclovir
  - 5.1.5.2.2.2.Famciclovir
  - 5.1.5.2.2.3.Valacyclovir
  - 5.1.5.2.2.4.Others
  - 5.1.5.3.By Route of Administration
  - 5.1.5.3.1.Oral
  - 5.1.5.3.2.Injectable
  - 5.1.5.3.3.Topical
  - 5.1.5.4.By End-user
  - 5.1.5.4.1.Hospital Pharmacies
  - 5.1.5.4.2.Retail Pharmacies
  - 5.1.5.4.3.Online Pharmacies
  - 5.1.5.4.4.Others
- 5.1.6.Canada
- 5.1.7.Mexico

All segments will be provided for all regions and countries covered

5.2.Europe
- 5.2.1.Germany
- 5.2.2.France
- 5.2.3.Italy
- 5.2.4.United Kingdom
- 5.2.5.Russia
- 5.2.6.Netherlands
- 5.2.7.Spain
- 5.2.8.Turkey
- 5.2.9.Poland
5.3.Asia-Pacific
- 5.3.1.India
- 5.3.2.China
- 5.3.3.Japan
- 5.3.4.Australia
- 5.3.5.Vietnam
- 5.3.6.South Korea
- 5.3.7.Indonesia
- 5.3.8.Philippines
5.4.South America
- 5.4.1.Brazil
- 5.4.2.Argentina
5.5.Middle East & Africa
- 5.5.1.Saudi Arabia
- 5.5.2.UAE
- 5.5.3.South Africa

6.Market Mapping, 2023

6.1.By Type
6.2.By Route of Administration
6.3.By End-user
6.4.By Region

7.Macro Environment and Industry Structure

7.1.Demand Supply Analysis
7.2.Import Export Analysis
7.3.Value Chain Analysis
7.4.PESTEL Analysis
- 7.4.1.Political Factors
- 7.4.2.Economic System
- 7.4.3.Social Implications
- 7.4.4.Technological Advancements
- 7.4.5.Environmental Impacts
- 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5.Porter's Five Forces Analysis
- 7.5.1.Supplier Power
- 7.5.2.Buyer Power
- 7.5.3.Substitution Threat
- 7.5.4.Threat from New Entrant
- 7.5.5.Competitive Rivalry

8.Market Dynamics

8.1.Growth Drivers
8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

9.1.Clinical Trials
9.2.Patent Landscape
9.3.Regulatory Approvals
9.4.Innovations/Emerging Technologies

10.Key Players Landscape

10.1.Competition Matrix of Top Five Market Leaders
10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4.SWOT Analysis (For Five Market Players)
10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

13.1.Bausch + Lomb Corporation
- 13.1.1.Company Details
- 13.1.2.Key Management Personnel
- 13.1.3.Products & Services
- 13.1.4.Financials (As reported)
- 13.1.5.Key Market Focus & Geographical Presence
- 13.1.6.Recent Developments
13.2.GlaxoSmithKline plc
13.3.Viatris Inc.
13.4.Novartis AG
13.5.Teva Pharmaceutical Industries Ltd.
13.6.Dr. Reddy's Laboratories, Ltd.
13.7.Abbott Laboratories
13.8.Pfizer Inc.
13.9.Sun Pharmaceuticals Industries Ltd.
13.10.Fresenius SE & Co KGaA

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

性器ヘルペス市場の評価：タイプ (診断・治療)・投与経路 (経口・注射・局所)・エンドユーザー (病院薬局・小売薬局・オンライン薬局・その他)・地域別の機会および予測 (2017～2031年)

Genital Herpes Market Assessment, By Type [Diagnosis, Treatment], Route of Administration [Oral, Injectable, Topical], End-user [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others], Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の性器ヘルペス市場の展望

第5章世界の性器ヘルペス市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Genital Herpes Market Outlook, 2017-2031F

5.Global Genital Herpes Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

性器ヘルペス市場の評価：タイプ (診断・治療)・投与経路 (経口・注射・局所)・エンドユーザー (病院薬局・小売薬局・オンライン薬局・その他)・地域別の機会および予測 (2017～2031年)

Genital Herpes Market Assessment, By Type [Diagnosis, Treatment], Route of Administration [Oral, Injectable, Topical], End-user [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others], Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の性器ヘルペス市場の展望

第5章 世界の性器ヘルペス市場の展望：地域別

第6章 市場マッピング

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Genital Herpes Market Outlook, 2017-2031F

5.Global Genital Herpes Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の性器ヘルペス市場の展望

第5章世界の性器ヘルペス市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項